Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Appointments: Top-Level Changes At J&J, Roche, Pierre Fabre, Nordic Nanovector, Inthera And DDF

Executive Summary

This week's announcements include changes at the top of Johnson & Johnson, Roche, Pierre Fabre, Nordic Nanovector, Inthera Bioscience and the Dementia Discovery Fund, plus new board appointments at Dova, Easton, Destiny Pharma and Abivax.

You may also be interested in...



Roche Partnering Casts Wide Net To Expand Company’s Neuroscience Pipeline

Roche completed 80 significant deals in 2019, neuroscience partnering head Tom Zioncheck said, many of which helped the company build its growing pipeline in neurological diseases.

Finance Watch: Global Ventures Step Into The Spotlight As The US Takes A Breather

Private Company Edition: I-Mab's $220m Series C round continued the trend of big investments in companies focused on or headquartered in China. Also, Shanghai-based Nuance brought in a combined $35m and European firms dominated recent small financings as US VC deals took a summer break.

Pipeline Watch: Phase III Readouts In Ovarian Cancer, Depression And Epidermolysis Bullosa Among Others

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

UsernamePublicRestriction

Register

SC123317

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel